Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved obinutuzumab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, prednisolone, and vincristine) as a treatment option for the treatment of patients with previously untreated advanced follicular lymphoma. The treatment regimen further defines eligibility criteria as requiring previously untreated, CD20-positive follicular lymphoma (grade 1 to 3a) with advanced disease stage III, stage IV, or stage II with bulk disease [tumor >= 7 cm in the greatest dimension]), ECOG status 0-2, and adequate hematological, renal, and liver status.

This is written in the approval document as:

Obinutuzumab in combination with CHOP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

Reimbursement

Incomplete Reimbursement

Obinutuzumab - ODMS 2019-05-01; cyclophosphamide, doxorubicin, and vincristine - N/A

Citation

Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (O-CHOP) Therapy - 21 day, 2026, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8393/549_Obinutuzumab-CHOP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisolone, Vincristine

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2019-05-01	Health Service Executive	Indication approved for reimbursement.